RMD Stock Recent News
RMD LATEST HEADLINES
ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.08 per share a year ago.
Resmed beat Wall Street estimates for fourth-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea.
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed, Inc. (RMD) shares up almost 3,142% since first Big Money outlier signal in 2000.
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, though still a bit short of my 12% annualized target. The July 2025 Top 15 stocks offer a 1.38% average dividend yield with an 18.78% 5-year dividend growth rate and are 23% undervalued.
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.